Susanne Arnold

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Novel Agents for Treatment of High-risk COVID-19 Positive Patients

Phase 2

Terminated

Conditions: COVID
Sars-CoV2

Interventions: Drug: Camostat Mesilate
Dietary Supplement: Artemesia annua
Drug: Ivermectin
Drug: Artesunate

First Posted Date: 2020-05-05

Last Posted Date: 2022-01-20

Lead Sponsor: Susanne Arnold

Target Recruit Count: 13

Registration Number: NCT04374019

Locations: 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States

Cisplatin + Radiation in SCCHN and Correlation with Oxidative Stress Markers

Phase 2

Active, not recruiting

Conditions: Carcinoma, Squamous Cell
Head and Neck Cancer

Interventions: Drug: Cisplatin
Radiation: XRT

First Posted Date: 2016-12-15

Last Posted Date: 2024-11-18

Lead Sponsor: Susanne Arnold

Target Recruit Count: 80

Registration Number: NCT02994069

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN

Phase 2

Completed

Conditions: Head and Neck Cancer
Larynx

Interventions: Radiation: Low dose fractionated radiation - 80cGy with chemotherapy
Drug: Docetaxel and Carboplatin AUC 6

First Posted Date: 2014-04-30

Last Posted Date: 2023-03-13

Lead Sponsor: Susanne Arnold

Target Recruit Count: 45

Registration Number: NCT02126969

Locations: 🇺🇸
University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States

A Protocol of Irinotecan for Carcinoma of the Lung

Phase 2

Withdrawn

Conditions: Lung Cancer

Interventions: Drug: Irinotecan

First Posted Date: 2012-07-31

Last Posted Date: 2014-05-30

Lead Sponsor: Susanne Arnold

Registration Number: NCT01654081

Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens

Completed

Conditions: Lung Cancer

Interventions: Other: Environmental sampling

First Posted Date: 2012-07-24

Last Posted Date: 2019-11-07

Lead Sponsor: Susanne Arnold

Target Recruit Count: 520

Registration Number: NCT01648166

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning

Not Applicable

Completed

Conditions: Lung Cancer

Interventions: Other: CT

First Posted Date: 2008-01-16

Last Posted Date: 2020-02-13

Lead Sponsor: Susanne Arnold

Target Recruit Count: 531

Registration Number: NCT00596310

Locations: 🇺🇸
Hazard ARH Regional Medical Center, Hazard, Kentucky, United States
🇺🇸
St. Claire Regional Medical Center, Morehead, Kentucky, United States
🇺🇸
Lake Cumberland Regional Hospital, Somerset, Kentucky, United States

and more 1 locations

Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Docetaxel
Radiation: Radiation

First Posted Date: 2006-09-20

Last Posted Date: 2015-06-08

Lead Sponsor: Susanne Arnold

Target Recruit Count: 10

Registration Number: NCT00378404

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer

Phase 2

Completed

Conditions: Stage IV Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Dexamethasone

First Posted Date: 2005-11-01

Last Posted Date: 2014-03-07

Lead Sponsor: Susanne Arnold

Target Recruit Count: 60

Registration Number: NCT00247416

Locations: 🇺🇸
Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
St. Claire Regional Medical Center, Morehead, Kentucky, United States
🇺🇸
Commonwealth Cancer Center, Danville, Kentucky, United States

and more 4 locations

Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Squamous Cell Carcinoma

Interventions: Radiation: Radiotherapy
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2005-09-15

Last Posted Date: 2023-05-16

Lead Sponsor: Susanne Arnold

Target Recruit Count: 40

Registration Number: NCT00176254

Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer

Phase 1

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: gemcitabine
Drug: paclitaxel
Radiation: radiation

First Posted Date: 2005-09-15

Last Posted Date: 2015-06-08

Lead Sponsor: Susanne Arnold

Target Recruit Count: 7

Registration Number: NCT00176241

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy